Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
Mosunetuzumab;Polatuzumab Vedotin
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study ### Output: Mosunetuzumab;Polatuzumab Vedotin